Cordant Inc’s AbbVie ABBV Stock Holding History

Cordant Inc’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-259	Closed	-$42K	–	61
2022 Q1	$42K	Buy	+259	New	+$37.6K	0.03%	60
2021 Q4	–	Sell	-3	Closed	–	–	73
2021 Q3	$0	Buy	+3	New	+$343	﹤0.01%	358

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cordant Inc's ABBV Position: Q2 2022 in Review

Cordant Inc sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 259 shares — an estimated $42K sold.

Cordant Inc first reported a position in ABBV in Q3 2021 and held it in 2 quarters. The position peaked at $42K in Q1 2022. 3,005 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

Cordant Inc reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
Cordant Inc sold 259 AbbVie shares in Q2 2022, an estimated $42K.
Cordant Inc first reported a position in AbbVie in Q3 2021 and held it in 2 quarters.
Cordant Inc's AbbVie position peaked at $42K in Q1 2022.
3,005 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Cordant Inc's 13F filing for Q2 2022, filed 17 Aug 2022.